1. Home
  2. ABCL vs AVXL Comparison

ABCL vs AVXL Comparison

Compare ABCL & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ABCL
  • AVXL
  • Stock Information
  • Founded
  • ABCL 2012
  • AVXL 2004
  • Country
  • ABCL Canada
  • AVXL United States
  • Employees
  • ABCL N/A
  • AVXL N/A
  • Industry
  • ABCL Biotechnology: Pharmaceutical Preparations
  • AVXL Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • ABCL Health Care
  • AVXL Health Care
  • Exchange
  • ABCL Nasdaq
  • AVXL Nasdaq
  • Market Cap
  • ABCL 1.1B
  • AVXL 956.7M
  • IPO Year
  • ABCL 2020
  • AVXL N/A
  • Fundamental
  • Price
  • ABCL $5.93
  • AVXL $9.64
  • Analyst Decision
  • ABCL Strong Buy
  • AVXL Strong Buy
  • Analyst Count
  • ABCL 5
  • AVXL 2
  • Target Price
  • ABCL $8.00
  • AVXL $44.00
  • AVG Volume (30 Days)
  • ABCL 6.2M
  • AVXL 1.2M
  • Earning Date
  • ABCL 11-06-2025
  • AVXL 08-12-2025
  • Dividend Yield
  • ABCL N/A
  • AVXL N/A
  • EPS Growth
  • ABCL N/A
  • AVXL N/A
  • EPS
  • ABCL N/A
  • AVXL N/A
  • Revenue
  • ABCL $32,875,999.00
  • AVXL N/A
  • Revenue This Year
  • ABCL $16.99
  • AVXL N/A
  • Revenue Next Year
  • ABCL $63.73
  • AVXL N/A
  • P/E Ratio
  • ABCL N/A
  • AVXL N/A
  • Revenue Growth
  • ABCL N/A
  • AVXL N/A
  • 52 Week Low
  • ABCL $1.89
  • AVXL $5.03
  • 52 Week High
  • ABCL $6.52
  • AVXL $14.44
  • Technical
  • Relative Strength Index (RSI)
  • ABCL 64.46
  • AVXL 54.87
  • Support Level
  • ABCL $5.57
  • AVXL $8.80
  • Resistance Level
  • ABCL $6.52
  • AVXL $10.38
  • Average True Range (ATR)
  • ABCL 0.39
  • AVXL 0.49
  • MACD
  • ABCL 0.09
  • AVXL 0.16
  • Stochastic Oscillator
  • ABCL 68.46
  • AVXL 63.59

About ABCL AbCellera Biologics Inc.

AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.

About AVXL Anavex Life Sciences Corp.

Anavex Life Sciences Corp is a clinical-stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system diseases with high unmet need. It analyzes genomic data from clinical studies to identify biomarkers, which are further used in the analysis of clinical trials. The company's focus is on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its various therapeutic candidates in different stages of development include Anavex 2-73 (Blacamesine), Anavex 3-71 (AF710B), Anavex 1-41, and Anavex 1066.

Share on Social Networks: